Trials / Active Not Recruiting
Active Not RecruitingNCT04520373
Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients
CELLTOP Part II: A Phase II Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Best Medical Management: Occupational and Physical Therapy | Observation while undergoing Occupational and Physical Therapy for 6 months |
| BIOLOGICAL | Autologous, Adipose Derived Mesenchymal Stem Cells | The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue. |
Timeline
- Start date
- 2020-06-25
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2020-08-20
- Last updated
- 2025-10-14
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04520373. Inclusion in this directory is not an endorsement.